Favorable policies are deployed, and the traditional Chinese medicine industry is expected to usher in an upward turning point

 Recently, 15 departments including the National Health Commission jointly issued the "14th Five-Year Plan for Healthy Aging".
It is reported that, affected by the news that China will vigorously develop traditional Chinese medicine elderly health services, the A-share pharmaceutical sector continues to rise
.
It is reported that the "14th Five-Year Plan for Healthy Aging" proposes to further leverage the unique advantages of traditional Chinese medicine health management in the implementation of basic public health service projects, and actively promote traditional Chinese medicine health management service projects for the elderly
.
Strive to achieve more than 75% of the Chinese medicine health management rate for the elderly aged 65 and above by 2025
.
Analysts believe that under the development background of aging population, changes in disease spectrum and national policy support, China's traditional Chinese medicine industry has a huge space for development
.
In 2022, with the support of policies and medical insurance, the industry is expected to usher in an upward turning point
.
China will vigorously develop traditional Chinese medicine elderly health services.
Affected by this news, today's A-share pharmaceutical sector continues to rise
.
For example, Chengda Pharmaceutical’s 20% daily limit, Guangshengtang rose more than 11%, and stocks such as Shutaishen, Tuoxin Pharmaceutical, West Point Pharmaceutical, and Miracle Pharmaceutical rose
.
In terms of the development of traditional Chinese medicine, traditional Chinese medicine enterprises such as Yiling Pharmaceutical and Taiji Group actively promote the steady growth of the industry
.
For example, in the continuous growth in the future, Yiling Pharmaceutical will mainly focus on three tracks, one of which is the traditional Chinese medicine industry
.
According to the industry, taking into account China's increasingly large aging population, increasing health awareness and the influence of policies issued by the state, the Chinese medicine industry may develop towards the integration of Internet, specialization, standardization and industrial chain in the future
.
Of course, Yiling Pharmaceutical also discovered this spring breeze.
In 2010, it deployed upstream raw material farming and established Yangzhou Zhihui Leech Breeding Company, which is engaged in the business of leech research and development, breeding, acquisition, processing and sales
.
In the same year, it acquired Grand Canal Logistics to dredge the entire industry chain
.
Acquired Beijing Yiling, making it one of the company's important standardized production bases
.
While laying out the production side, Yiling Pharmaceutical also laid out the medical e-commerce field, and established Yiling Health City Technology Co.
, Ltd.
and Hebei Grand Canal Pharmaceutical Co.
, Ltd. .
In the process of development, Taiji Group has accelerated its transformation endogenously, and achieved leapfrog development through its extension expansion
.
The company proposes a development direction in terms of strategic goals: to take modern Chinese medicine manufacturing as the main line, and at the same time to supplement with special chemical drugs of narcotic and regional commercial enterprises
.
Through endogenous development and external expansion, the company strives to reach 50 billion yuan in operating income at the end of the "14th Five-Year Plan"
.
From the perspective of endogenous growth, it is expected that the compound growth rate of the income end of the industrial sector will reach 30% in 2022-2025, and the net profit rate is expected to recover to 10%.
It is expected that the industry will contribute 1.
5-2 billion yuan in net profit in 2025
.
Traditional Chinese medicine is a national treasure and an important resource.
The top-level design of traditional Chinese medicine boosts the overall situation, and the industry continues to enter high-quality development
.
During the "14th Five-Year Plan", China will vigorously develop traditional Chinese medicine elderly health services, which will further promote the development of the traditional Chinese medicine industry
.
However, during the "13th Five-Year Plan" period, the development of traditional Chinese medicine has become a national strategy.
China has successively issued the "Traditional Chinese Medicine Law" and opinions and policy measures to promote inheritance, innovation and development, and launched a major medical insurance support policy at the end of 2021.
The entire industry chain has made coherent top-level design and planning, various policies have been steadily advanced, and the cause of traditional Chinese medicine is booming
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.